D. E. Shaw & Co., Inc. Myovant Sciences Ltd. Transaction History

D. E. Shaw & Co., Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$24.03 - $27.02 $63,535 - $71,440	-2,644 Reduced 6.32%	39,213 $1.06 Million
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $485,541 - $855,557	41,857 New	41,857 $752,000
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $122,340 - $231,000	-15,725 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $178,950 - $257,889	15,725 New	15,725 $209,000
Q1 2021 May 17, 2021	SELL	$20.46 - $25.18 $549,964 - $676,838	-26,880 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $370,944 - $742,425	26,880 New	26,880 $742,000
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $78,897 - $360,859	-18,785 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.19 - $9.46 $97,494 - $177,706	18,785 New	18,785 $98,000
Q2 2018 Aug 14, 2018	SELL	$19.2 - $25.14 $6.72 Million - $8.8 Million	-350,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $3.48 Million - $5.41 Million	350,000	350,000 $5.42 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.